These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22618883)

  • 1. Is an immune reaction required for malignant transformation and cancer growth?
    Prehn RT; Prehn LM
    Cancer Immunol Immunother; 2012 Jul; 61(7):963-6. PubMed ID: 22618883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The initial immune reaction to a new tumor antigen is always stimulatory and probably necessary for the tumor's growth.
    Prehn RT
    Clin Dev Immunol; 2010; 2010():. PubMed ID: 20811480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The flip side of immune surveillance: immune dependency.
    Prehn RT; Prehn LM
    Immunol Rev; 2008 Apr; 222():341-56. PubMed ID: 18364013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fresh look at tumor immunosurveillance and immunotherapy.
    Smyth MJ; Godfrey DI; Trapani JA
    Nat Immunol; 2001 Apr; 2(4):293-9. PubMed ID: 11276199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of T- and B-cell immunity in the pathogenesis of cancer].
    Savchenko AA; Borisov AG; Kudryavtsev IV; Moshev AV
    Vopr Onkol; 2015; 61(6):867-75. PubMed ID: 26995973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer and the immune system.
    Karakousis CP
    J Med; 1980; 11(5-6):449-58. PubMed ID: 6187876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor immunity: myeloid leukocytes control the immune landscape.
    Rutkowski MR; Stephen TL; Conejo-Garcia JR
    Cell Immunol; 2012; 278(1-2):21-6. PubMed ID: 23121972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor immunity and immunotherapy.
    Boura P; Kountouras J; Lygidakis NJ
    Hepatogastroenterology; 2001; 48(40):1040-4. PubMed ID: 11490795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
    Cancel JC; Crozat K; Dalod M; Mattiuz R
    Front Immunol; 2019; 10():9. PubMed ID: 30809220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New solid tumor targets for therapeutic monoclonal antibodies.
    Papkoff J
    Expert Opin Ther Targets; 2007 May; 11(5):585-8. PubMed ID: 17465718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
    Finn OJ
    Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunoediting from immune surveillance to immune escape.
    Kim R; Emi M; Tanabe K
    Immunology; 2007 May; 121(1):1-14. PubMed ID: 17386080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
    Ward JP; Gubin MM; Schreiber RD
    Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [1 of the pathways for normalization of populations of malignant cells].
    Shuklinov VA
    Tsitologiia; 1985 Mar; 27(3):268-75. PubMed ID: 3887700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of tumor growth and metastases in mice bearing a malignant fibrosarcoma by T cell-mediated immune response to oncofetal antigens.
    Gautam S; Deodhar SD
    Am J Reprod Immunol (1980); 1983; 3(3):141-8. PubMed ID: 6603172
    [No Abstract]   [Full Text] [Related]  

  • 17. T-cell death and cancer immune tolerance.
    Lu B; Finn OJ
    Cell Death Differ; 2008 Jan; 15(1):70-9. PubMed ID: 18007660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunoreactivity in tumor growth].
    Fel' VIa
    Vopr Onkol; 1987; 33(4):99-106. PubMed ID: 3296438
    [No Abstract]   [Full Text] [Related]  

  • 19. Hitting the Target: How T Cells Detect and Eliminate Tumors.
    Zamora AE; Crawford JC; Thomas PG
    J Immunol; 2018 Jan; 200(2):392-399. PubMed ID: 29311380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
    J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.